Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5652W HIGH $13.29
Volume
3.20 M
Value Traded
40.15 M
Short % Float
9.16%
Days to Cover
5.8
-1.8%Week
-2.56%1 Month
-0.08%3 Month
+89.74%6 Month
-23.76%5 Year
-98.35%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
718.13 M
EPS (TTM)
-2.15
P/E Ratio
-
Ent. Value
590.19 M
Total Shares
56.41 M
Float Shares
45.70 M
Insiders
12.34%
Institutions
79.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ATXS Catalyst Timeline
Dated clinical, regulatory and corporate events for Astria Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How ATXS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-09-30 | STAR-0310 (monoclonal antibody OX40 antagonist) | Phase 1a data readout | Phase 1a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| navenibart Small moleculeNCT06842823 | Hereditary Angioedema | Phase 3 | ACTIVE NOT_RECRUITING | 331 | Jun 1, 2027 | ||||||
| STAR-0215 Small moleculeNCT06007677 | Hereditary Angioedema | Phase 2 | ACTIVE NOT_RECRUITING | 97 | Mar 1, 2031 | ||||||
| STAR-0310 Small moleculeNCT06782477 | Undisclosed | Phase 1 | ACTIVE NOT_RECRUITING | 40 | Jan 1, 2026 | ||||||
| Autoinjector, Vial and syringe UnknownNCT07635095 | Undisclosed | Phase 1 | RECRUITING | 180 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ATXS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| STAR-0215 | hereditary angioedema | Phase 1a | 2022-12-15 | well-tolerated at all doses studied; estimated half-life of STAR-0215 up to 110 days; sustained target engagement with plasma kallikrein inhibition for at least three monthsRead More | Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects -- Shown Early Proof of Concept of STAR-0215's Profile as a Long-Acting Plasma Kallikrein InhibRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Morabito ChristopherOfficer (Chief Medical Officer) | Option | 10,000 10,000 held | $3.87 | 04/01/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in ATXS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 1.5 % (7.1 %) | 84.89 M | 6.49 M |
Ownership Trends
ATXS Short Interest
Shares sold short, counted twice a month.
9.16%
Short % of Float
of tradable shares sold short
4.2M
Shares Sold Short
-27.3% vs prior count
5.8 High
Days to Cover
trading days of normal volume to buy every short share back
723.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATXS ranks across every disease it competes in
Competitive Position is a premium feature
See how ATXS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATXS News
About Astria Therapeutics, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next ATXS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime